OptiMed Technology, Inc. is a biotechnology company headquartered in Buffalo, New York. Our mission is to promote the clinical translation of fundamental lab research into human clinical treatments that will reduce pain and suffering, enhance quality of life and improve oral health.

​

OptiMed has developed a delivery platform, utilizing nano-technology to control and sustain the release of biological payloads to enhance oral health. Our current plans are to bring two products to market, digoDentTM and mycoDentTM. We will focus on developing digoDentTM in the first two years, with mycoDentTM to follow.

​

Drug Induced Gingival Overgrowth (DIGO) and Candida Albicans (oral thrush) are just two of many oral hygiene problems affecting millions of people every year.  OptiMed was formed to develop and market products designed to combat these and other afflictions.

DIGO is a side effect of commonly prescribed drugs such as anti-hypertensive CCBs, anti-convulsants and immuno-suppressants. About 20 million patients, 6% of the U.S. population, are currently prescribed those medications and are at risk of DIGO. About 1 million patients in the U.S. are currently afflicted with DIGO.

​

DIGO causes both physical and psychological problems. Gingival overgrowth is where the gums grow due to fibrosis, it can completely cover the teeth, interfering with chewing and speaking. Overgrowth of the front teeth is common in hypertensive and transplant patients which can displace and destroy affected teeth. Overgrown tissue creates pockets that are difficult to reach with brushing or flossing, leading to plaque buildup, infection, cavities, periodontal disease, halitosis and systemic infections. DIGO can also lead to depression, anxiety, fear, and pain, especially when it causes aesthetic problems on the front teeth.

Scaling, root planning, gingivectomy and periodontal flap surgery are procedures that are currently used to treat DIGO. However, those surgical approaches have limited efficacy as the DIGO can reoccur within months or even weeks. At this time there are no drugs to treat or cure DIGO.

​

Statistics show that complete scaling for DIGO costs about $900 per treatment and requires an average of four times per year. Gingivectomies typically cost between $500 and $1500 and they too are temporary solutions.

We have developed an alternative approach to treat DIGO. Our benchtop protocol has successfully demonstrated proof of principle and efficacy. We are now working on increasing throughput by developing a sustainable, cost-effective, FDA compliant process to generate quality products for human clinical applications.

​

The first product to market, digoDent, has shown significant efficacy in lab  tests to actively combat DIGO. All materials used in digoDent are FDA-cleared. Our approach provides a unique intellectual niche in compounding formulation and process, involving proprietary knowledge and methods that are patent pending.